We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMVRP
LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical
company focused on respiratory diseases, is pleased to announce the
appointment of Nplus1 Singer Advisory LLP (together with its associates,
"N+1 Singer") as nominated adviser and UK corporate broker to the
Company with immediate effect.
For further information contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer mailto:info@veronapharma.com info@veronapharma.com
Victoria Stewart, Director of Communications
-----------------------------------------------------------------------
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Mia Gardner (Corporate Broking)
ICR, Inc. (US Media and Investor enquiries) Tel: +1 203-919-7905
Darcie Robinson mailto:Darcie.Robinson@icrinc.com Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
mailto:Stephanie.Carrington@icrinc.com Stephanie.Carrington@icrinc.com
-----------------------------------------------------------------------
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that
has been shown to act as both a bronchodilator and an anti-inflammatory
agent in a single compound. Ensifentrine is currently in Phase 2b
clinical development for the maintenance treatment of COPD and is
planned to enter Phase 3 trials for this indication in 2020. Verona
Pharma is also developing ensifentrine for the treatment of cystic
fibrosis and asthma.
(END) Dow Jones Newswires
May 01, 2019 02:00 ET (06:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
